|
|
|
|
|
|||||||
|
Session 48
Poster Session
Protein and Inactivated Virus Vaccines 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 289-W. | Vaccination of Rhesus Macaques with HIV-1 Tat Protein P. Silvera*1, J. Greenhouse1, J. Yalley-Ogunro1, M. W. Richardson2, J. Mirchandani2, K. Khalili2, J-F. Zagury3, M. Lewis1, and J. Rappaport2 1Southern Res. Inst., Frederick, MD; 2Temple Univ., Philadelphia, PA; and 3Univ. Pierre et Marie Curie, Paris, France
| ||
| 290-W. | Characterization of Humoral Immune Response against the Wild Type and Variable Loop-Deleted HIV-1 Envelope Glycoproteins Y. B. Kim*, D. P. Han, C. Cao, and M. W. Cho NIH, Bethesda, MD
| ||
| 291-W. | Enhanced Immunogenicity of Nasally Administered HIV Peptides Using Mucoadhesive Polymers S. K. Nordone* and H. F. Staats Duke Univ. Med. Ctr., Durham, NC
| ||
| 292-W. | Intranasal Immunization with Inactivated gp120-Depleted HIV-1 Immunogen (Remune) plus CpG ODN Induces Potent Immune Responses in the Genital Tract and Protection against Intravaginal Challenge N. Dumais1, J. Jiang*1, R. B. Moss2, H. L. Davis3, and K. L. Rosenthal1 1McMaster Univ. Hlth. Sci. Ctr., Hamilton, ON, Canada; 2Immune Response Corp., Carlsbad, CA; and 3 Coley Pharmaceutical Group, Ottawa, ON, Canada
| ||
| 293-W. | Novel Method of HIV-1 Inactivation and Its Application towards Development of a Whole-Killed HIV Vaccine P. Ilyinskii, L. Lallos, and T. Castor* Aphios Corp., Woburn, MA
|
